CODX - コ・ダイアグノスティックス （Co-Diagnostics Inc.） コ・ダイアグノスティックスCODXのチャート
CODXの企業情報
| symbol | CODx |
|---|---|
| 会社名 | Co-Diagnostics Inc （コ・ダイアグノスティックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Co-Diagnostics Inc. is a molecular diagnostics company. The Company is engaged in developing manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis a drug resistant tuberculosis test hepatitis B and C Malaria dengue human immunodeficiency virus and Zika virus all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. コ・ダイアグノスティックスは米国の医療関連企業。主に、医療診断における試薬の開発・製造・販売に従事する。核酸分子の検出および分析の診断テストに使用される試薬を開発、完結型ラボ・システムを販売する。また、病気や遺伝的疾患の治療のため、DNAベ―スの試験プラットフォ―ムを開発する。本社所在地はユタ州ソルト・レ―ク・シティ―。 Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. |
| 本社所在地 | 2401 S. Foothill Drive Suite D Salt Lake City UT 84109 USA |
| 代表者氏名 | Dwight H. Egan ドワイト・エガン |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 801-278-9769 |
| 設立年月日 | 41365 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2017年 |
| 従業員数 | 15人 |
| url | www.codiagnostics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/codx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -5.87956 |
| 終値（lastsale） | 2.3054 |
| 時価総額（marketcap） | 28467141.4458 |
| 時価総額 | 時価総額（百万ドル） 27.78306 |
| 売上高 | 売上高（百万ドル） 0.02460 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 26.25479 |
| 当期純利益 | 当期純利益（百万ドル） -8.08090 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Co-Diagnostics Inc revenues increased from $2K to $19K. Net loss increased 72% to $2.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 46% to $655K (expense) Sales and marketing increase of 26% to $239K (expense). |
CODXのテクニカル分析
CODXのニュース
Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022 2022/09/12 13:30:00 Co-Diagnostics
SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Reminds Investors of a Lawsuit Against Co-Diagnostics Inc. 2022/09/08 15:47:52 EIN News
Class action lawsuit charges Co-Diagnostics and certain of its top executive officers with violations of the Securities Exchange Act of 1934.
A COVID-19 testing startup with ''no history of success'' faces lawsuit over accuracy claims 2022/09/08 01:50:26 USA Today
Co-Diagnostics faces a federal lawsuit for allegedly making false, misleading statements to inflate its stock price to benefit directors.
Co-Diagnostics: Hold Thesis Remains Well Intact (NASDAQ:CODX) 2022/09/07 14:46:41 Seeking Alpha
We reiterate the hold thesis on Co-Diagnostics following Q2 FY22 earnings as Covid-19 turnover continues to diminish. Read our analysis of CODX here.
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Co-Diagnostics (CODX) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Class Action Filed 2022/09/06 19:53:00 GlobeNewswire
SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Co-Diagnostics, Inc. (NASDAQ: CODX) investors who suffered significant losses to submit your losses now .
Co-Diagnostics extends gains on monkeypox test development 2022/05/27 19:08:21 Seeking Alpha
The shares of Co-Diagnostics (CODX) are trading higher for the third straight session on Friday in solidarity with makers of monkeypox vaccines and therapeutics after molecular…
Why Co-Diagnostics Trounced the Market on Thursday 2022/05/26 22:01:24 The Motley Fool
The company is not monkeying around with the latest possible global health menace.
Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus 2022/05/26 13:30:00 PR Newswire
SALT LAKE CITY, May 26, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed the principal design…
Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q1 2022 Results - Earnings Call Transcript 2022/05/13 00:08:14 Seeking Alpha
Co-Diagnostics, Inc. (NASDAQ:NASDAQ:CODX) Q1 2022 Earnings Conference Call May 12, 2022, 16:30 ET Company Participants Andrew Benson - Head, IR Dwight Egan - Chairman, CEO & President…
Co-Diagnostics Stock Surges As Q1 Results Surpass Street Expectations 2022/05/12 23:09:12 Benzinga
Co-Diagnostics Inc (NASDAQ: CODX ) reported first-quarter revenue growth of 13.4% year-over-year to $22.7 million , beating the consensus of $20.17 million. Co-Diagnostics Inc (NASDAQ: CODX ) reported first-quarter revenue growth of 13.4% year-over-year to $22.7 million , beating the consensus of $20.17 million. The increase in revenue is attributable to the Logix Smart™ COVID-19 Test sales. EPS was $0.34 for the quarter, above the consensus of $0.17. The gross margin expanded by 188 bps to 85.5%. Operating … Full story available on Benzinga.com
Co-Diagnostics, Inc. Announces Second Quarter 2021 Earnings Release Date And Webcast 2021/08/04 15:30:00 Co-Diagnostics
Co-Diagnostics Inc Shares Close the Week 38.3% Higher - Weekly Wrap 2021/07/24 09:37:09 Kwhen Finance
Co-Diagnostics Inc (CODX) shares closed this week 38.3% higher than it did at the end of last week. The stock is currently up 13.3% year-to-date, down 50.4% over the past 12 months, and up 81.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 rose 0.2%. Trading Activity Shares traded as high as $11.20 and as low as $7.69 this week.Shares closed 70.6% below its 52-week high and 30.1% above its 52-week low.Trading volume this week was 341.6% higher than the 10-day average and 778.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at -0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 1.2% higher than its 5-day moving average, 8.6% higher than its 20-day moving average, and 2.2% higher than its 90-day moving average.
Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -67.8% The company's stock price performance over the past 12 months lags the peer average by -218.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -20.7% lower than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Co-Diagnostics gets Republic of Korea patent for its CoPrimer technology 2021/07/22 14:27:15 Seeking Alpha
Co-Diagnostics, Inc. Strengthens Intellectual Property Portfolio with New International CoPrimer Patent 2021/07/22 13:30:00 Co-Diagnostics
Proactive news headlines including Co-Diagnostics, Esports Entertainment, Versus Systems and Plurilock Security 2021/06/18 17:36:00 Intrado Digital Media
New York , June 18, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies: